VAM
SAGE

Visium Asset Management’s Sage Therapeutics SAGE Stock Holding History

Visium Asset Management’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-7,395
Closed -$223K – 163
2016
Q2 		$223K Sell
7,395
-1,552,527
-100% -$51.8M 0.02% 311
2016
Q1 		$50M Buy
1,559,922
+484,613
+45% +$17.1M 0.85% 21
2015
Q4 		$62.7M Buy
1,075,309
+172,361
+19% +$8.54M 0.94% 17
2015
Q3 		$38.2M Buy
902,948
+246,027
+37% +$15.2M 0.52% 32
2015
Q2 		$48M Buy
656,921
+631,921
+2,528% +$40.6M 0.68% 25
2015
Q1 		$1.26M Buy
+25,000
New +$1.07M 0.02% 492

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Visium Asset Management's SAGE Position: Q3 2016 in Review

Visium Asset Management sold out of Sage Therapeutics (SAGE) in Q3 2016, closing a stake of 7,395 shares — an estimated $223K sold.

Visium Asset Management first reported a position in SAGE in Q1 2015 and held it in 6 quarters. The position peaked at $62.7M in Q4 2015. 153 funds tracked by Wall St. Rank hold SAGE as of Q3 2016.

  • Visium Asset Management reported no remaining Sage Therapeutics position as of Q3 2016 after selling out during the quarter.
  • Visium Asset Management sold 7,395 Sage Therapeutics shares in Q3 2016, an estimated $223K.
  • Visium Asset Management first reported a position in Sage Therapeutics in Q1 2015 and held it in 6 quarters.
  • Visium Asset Management's Sage Therapeutics position peaked at $62.7M in Q4 2015.
  • 153 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2016.

Based on Visium Asset Management's 13F filing for Q3 2016.